Worsening Graves' Ophthalmopathy after radioactive iodine therapy

Article Sidebar

PDF (Español (España))
Published Dec 2, 2020

Main Article Content

Víctor Luna-Rodríguez
Víctor Luna Rodríguez (General Physician – Hospital San Fernando Clinic, Panama)
Hildebrando Luna-Jiménez
Hildebrando Luna Jiménez (Specialist in Med. Internal and Endocrinology – Clínica Hospital San Fernando, Panama).

Abstract

Graves‘Ophthalmopathy is one of the most enigmatic clinical findings in Endocrinology. The fact that the most used treatment modality for hyperthyroidism could produce development or progression of the exophthalmos seen in these patients have led to extensive research around the world. The data are in some ways ambiguous or confusing because of the conflicting results obtained from the different research studies. This is a little review of the literature, trying to cover the most prominent points of view from the leaders in the study of this issue.

Downloads

Download data is not yet available.

Article Details

How to Cite
Luna-RodríguezV., & Luna-JiménezH. (2020). Worsening Graves’ Ophthalmopathy after radioactive iodine therapy. Acta Académica, 28(Mayo), 247-251. Retrieved from http://201.196.25.14/index.php/actas/article/view/944
Issue
Vol 28 No Mayo (2001)
Section
Acta Médica

Los autores que publiquen en la Revista ACTA ACADÉMICA aceptan las siguientes condiciones:

De acuerdo con la legislación de derechos de autor, la Revista ACTA ACADÉMICA  reconoce y respeta el derecho moral de los autores, así­ como la titularidad del derecho patrimonial, el cual será cedido a la revista para su difusión en acceso abierto.

La Revista ACTA ACADÉMICA  no realiza cargos a las/los autoras/es por enviar y procesar artí­culos para su publicación.

Todos los textos publicados por la Revista ACTA ACADÉMICA  –sin excepción– se distribuyen amparados bajo la licencia Creative Commons que permite a terceros utilizar lo publicado siempre que mencionen la autorí­a del trabajo y a la primera publicación en esta revista.

References

1. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A, “Relation between therapy for hyperthyroidism and the course of Graves´ ophthalmopathy”. N Engl J. Med 1998 Jan 8; 338(2):73-8.
2. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. “Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hiperthyroidism” N Engl J Med 1989 Nov 16;32(20):1349-52.
3. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell‘Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A. “Cigarette smoking and treatment outcomes in Graves’ophthalmopathy”. Ann Intern Med 1998 Oct 15;129 (8):632-5.
4. Barth A, Probst P, Burgi H. “Identification of a subgroup of Graves ‘disease patients at higher risk for severe ophthalmopathy after radioiodine”. J Endocrinol Invest 1991 Mar; 14 (3):209-12.
5. Clutter W. E. “Radioiodine plus prednisone prevented development or progression of ophthalmopathy in patients with Graves hyperthyroidism” (Commentary) ACP Journal Club 1998 May/June; 128 (3):71.
6. DeGroot LJ, Gorman CA, Pinchera A, Bartalena L, Marocci C, Wiersinga MF, Prummel MF, Wartofsky L. “Therapeutic controversies. Radiation and Graves’ ophthalmopathy Retro-orbital radiation and radioactive iodine ablation of the thyroid may be good for Graves‘ophthalmopathy”. J Clin Endocrinol Metab; Thyroid Rounds 1994-1996.
7. Fernández Sánchez JR, Rosell Pradas J, Carazo Martínez O, Torres Vela E, Escobar Jiménez F, Garbin Fuentes I, Vara Thorbeck R. “Graves‘ ophthalmopathy after subtotal thyroidectomy and radioiodine therapy”. Br J Surg 1993 Sep; 80(9):1134-6.
8. Greenspan FS, Strwler GJ. Basic & Clinical Endocrinology, 5th Edition. Appleton & Lange, 1997. Ch.7, pp. 217, 223, 233, 234, 235, 236, 240.
9. Gwinup G, Elias AN, Ascher MS. “Effect on exophthalmos of various methods of treatment of Graves‘disease”. JAMA 1982 Apr 16; 247(15):2135-8.
10. Hall R, Evered D, Greene R. A Colour Atlas of Endocrinology. London, Wolfe Medical Publications Ltd, 1979; Ch. 3, pp.51-60.
11. Jameson JL, Molitch ME: The Endocrine Society’s Clinical Endocrinology Update ´96 Syllabus, The Endocrine Society Press, 1996. Section 5. Page 242.
12. Kung AW, Yau CC, Cheng A. “The incidence of ophthalmopathy after radioiodine therapy for Graves’disease: prognostic factors and the role of methimazole”. J. Clin Endocrinol Metab 1994 Aug; 79 (2):542-6.
13. Manso PG, Furlanetto RP, Wolosker AM, Paiva ER, de Abreu MT, Maciel RM. “Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves’ hyperthroidism”. Thyroid 1998 Jan; 8 (1):49-52.
14. Neal JM: Case Studies in Endocrinology, Diabetes, and Metabolism. A Problem Oriented Approach. New York, IGAKU-SHOIN Medical Publishers, INC., 1996; Ch.3, page 57.
15. Souhami RL, Moxham J. Textbook of Medicine. Third Edition, Churchill Livingstone 1997; Ch. 19, pp. 750-751.
16. Sridama V, De Grrot LJ. “Treatment of Graves‘disease and the course of ophthalmopathy”. Am J Med 1989 Jul; 87(1):70-3.
17. Tallstedt L, Lundell G. “Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective”. Thyroid 1997 Apr; 7 (2):241-5.
18. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A.
















“Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group”. N Engl J Med 1992 Jun 25; 326 (26):1733-8.
19. Tierney LM, JR., McPhee SJ, Papadakis MA: Current Medical Diagnosis & Treatment 1998. 37th Edition Stamford, Appleton & Lange, 1998; Ch.26, pp. 1051, 1053-1055.
20. Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B, “Graves’ hiperthyroidism treatment with antithyroid drugs, surgery, or radioiodine-a prospective, randomized study. Thyroid Study Group”. J Clin Endocrinol Metab 1996 Aug; 81 (8):2986-93.
21. Ursu Hl, Dumitriu L, Grigorie D, Simescu M, Vaida E, Belgum M, Popovici D. “Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume. Graves’ ophthalmopathy, thyrotoxic heart disease)”. Rom J Endocrinol 1993; 31 (3-4):155-63.